In addition, some scholars have found that CD24+/CD44+- EPCAM+ cell subsets have specific gene expression profiles, and these stemness-related cell subclones in HCC enable tumor cells to acquire great genetic richness, leading to the failure of HCC targeted therapy (Ho et al., 2019). The gene discussed is CD44; the disease is hepatocellular carcinoma.